FIGURE 3.

Potential disposition pathways of remibrutinib. ^aOral dose equals 100%. ^bFirst pass for intestine and liver, calculated using PBPK modeling. ^cFractional contribution of CYP3A4 based on clinical DDI results and sum of minor oxidative pathways (<2%), hydrolysis, GSH conjugates, and biliary secretion. Disposition values are derived from observed PK parameters listed in Table 1. DDI, drug‐drug interaction; GSH, glutathione; PBPK, physiologically‐based pharmacokinetic model, PK, pharmacokinetic